Ixazomib is an oral proteasome inhibitor used primarily in the treatment of multiple myeloma, a type of blood cancer. It was the first oral proteasome inhibitor approved by the U.S. Food and Drug Administration (FDA) for this purpose. It is often marketed under the brand name Ninlaro.
